IDEXX Laboratories Current Debt
| IDXX Stock | USD 487.07 3.39 0.70% |
IDEXX Laboratories has over 947.88 Million in debt which may indicate that it relies heavily on debt financing. At this time, IDEXX Laboratories' Short and Long Term Debt Total is fairly stable compared to the past year. Short and Long Term Debt is likely to rise to about 340.3 M in 2024, whereas Net Debt is likely to drop slightly above 255.9 M in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce IDEXX Laboratories' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
IDEXX Laboratories' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. IDEXX Laboratories' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps IDEXX Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect IDEXX Laboratories' stakeholders.
For most companies, including IDEXX Laboratories, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running IDEXX Laboratories the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 27.8496 | Book Value 18.931 | Operating Margin 0.3101 | Profit Margin 0.2326 | Return On Assets 0.2263 |
IDEXX |
IDEXX Laboratories Financial Leverage Rating
IDEXX Laboratories bond ratings play a critical role in determining how much IDEXX Laboratories have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for IDEXX Laboratories' borrowing costs.| Piotroski F Score | 7 Strong |
| Beneish M Score | -2.01 Possible Manipulator |
IDEXX Laboratories Debt to Cash Allocation
As IDEXX Laboratories follows its natural business cycle, the capital allocation decisions will not magically go away. IDEXX Laboratories' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 947.88 M in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist IDEXX Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, IDEXX Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like IDEXX Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for IDEXX to invest in growth at high rates of return. When we think about IDEXX Laboratories' use of debt, we should always consider it together with cash and equity.IDEXX Laboratories Total Assets Over Time
IDEXX Laboratories Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the IDEXX Laboratories' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of IDEXX Laboratories, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a an IDEXX Laboratories debt ratio should be compared their industry average or other competing firms.IDEXX Net Debt
Net Debt |
|
Understaning IDEXX Laboratories Use of Financial Leverage
IDEXX Laboratories financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures IDEXX Laboratories's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of IDEXX Laboratories assets, the company is considered highly leveraged. Understanding the composition and structure of overall IDEXX Laboratories debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to IDEXX Laboratories' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of IDEXX Laboratories' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | 493.9 M | 255.9 M | |
| Short and Long Term Debt Total | 947.9 M | 995.3 M | |
| Short Term Debt | 325 M | 208.6 M | |
| Long Term Debt | 622.9 M | 380.8 M | |
| Long Term Debt Total | 798.5 M | 502 M | |
| Short and Long Term Debt | 325 M | 340.3 M | |
| Net Debt To EBITDA | 0.45 | 0.47 | |
| Debt To Equity | 0.64 | 0.67 | |
| Interest Debt Per Share | 10.98 | 11.53 | |
| Debt To Assets | 0.29 | 0.20 | |
| Long Term Debt To Capitalization | 0.30 | 0.29 | |
| Total Debt To Capitalization | 0.39 | 0.28 | |
| Debt Equity Ratio | 0.64 | 0.67 | |
| Debt Ratio | 0.29 | 0.20 | |
| Cash Flow To Debt Ratio | 0.96 | 0.91 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of IDEXX Laboratories Fundamentals Over Time. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.102 | Earnings Share 10.31 | Revenue Per Share 44.828 | Quarterly Revenue Growth 0.071 | Return On Assets 0.2263 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.